Two cases of congenital dysfibrinogenemia associated with thrombosis – Fibrinogen Praha III and Fibrinogen Plzeň

Summary

Congenital dysfibrinogenemia is a rare disease characterised by inherited abnormality in the fibrinogen molecule, resulting in functional defects. Two patients, a 26-year-old woman and a 61-year-old man, both with history of thrombotic events, had abnormal coagulation test results. DNA sequencing showed the heterozygous γY363N mutation (Fibrinogen Praha III) and the heterozygous Aα N106D mutation (Fibrinogen Plzeň), respectively. Fibrin polymerisation, after addition of either thrombin or reptilase, showed remarkably delayed polymerisation in both cases. Fibrinolysis experiments showed slower tPA initiated lysis of clots. SDS-PAGE did not show any difference between normal and Praha III and Plzeň fibrinogens. Both mutations had a significant effect on platelet aggregation. In the presence of either ADP or TRAP, both mutations caused the decrease of platelet aggregation. SEM revealed abnormal clot morphology, with a large number of free ends and narrower fibres of both fibrin Praha III and Plzeň. Praha III mutation was situated in the polymerisation pocket “a”. The replacement of the bulky aromatic side chain of tyrosine by the polar uncharged small side chain of asparagine may lead to a conformational change, possibly altering the conformation of the polymerisation pocket. The Plzeň mutation is situated in the coiled-coil connector and this replacement of polar uncharged asparagine residue by polar acidic aspartate changes the alpha-helical conformation of the coiled-coil connector;and may destabilise hydrogen bonds in its neighborhood. Although both mutations are situated in different regions of the molecule, both mutations have a very similar effect on fibrinogen functions and both are connected with thromboses.

Keywords

Dysfibrinogenemia - fibrinogen - missense mutation - pulmonary embolism - thrombosis

• References

• 1 UCSC Genome Browser. http://genome.ucsc.edu/cgi-bin/hgTracks?position=chr4:155100001-161500000&hgsid=106991619 Accessed 5. 11. 2008
• 2 Medved L, Weisel JW. Recommendations for nomenclature on fibrinogen and fibrin. J Thromb Haemost 2009; 07: 355-359.
• 3 Pratt KP. et al. The primary fibrin polymerisation pocket: Three-dimensional structure of a 30-kDa C-terminal γ chain fragment complexed with the peptide Gly-Pro-Arg-Pro. Proc Natl Acad Sci USA 1997; 94: 7176-7181.
• 4 Hanss M, Biot F. A Database for Human Fibrinogen Variants. Ann NY Acad Sci. 2001 936. 89-90 Available at: http://www.geht.org/databaseang/fibrinogen release 28.
• 5 Monaldini L. et al. Mutational screening of six afibrinogenemic patients: Identification and characterization of four novel molecular defects. Thromb Haemost 2007; 97: 546-551.
• 6 Brennan SO. et al. Congenital hypodysfibrinogenaemia (Fibrinogen Des Moines) due to a γ320Asp deletion at the Ca2+ binding site. Thromb Haemost 2007; 98: 467-469.
• 7 Davis RL, Brennan SO. Fibrinogen Tolaga Bay: A novel γAla341 Val mutation causing hypofibrinogenaemia. Thromb Haemost 2007; 98: 1136-1138.
• 8 Flood VH. et al. Fibrinogen Hershey IV: A novel dysfibrinogen with a γV411I mutation in the integrin αIIbβ3 binding site. Thromb Haemost 2008; 99: 1008-1012.
• 9 Kotlín R. et al. Three cases of abnormal fibrinogens: Šumperk (BβHis67Leu), Uniãov (BβGly414Ser), and Brno (γArg275His). Thromb Haemost 2008; 100: 1199-1200.
• 10 Davis RL. et al. Fibrinogen Foxton: A novel BβA277V mutation causing low normal plasma fibrinogen concentration. Thromb Haemost 2008; 100: 708-710.
• 11 Okumura N. et al. Fibrinogen Matsumoto I: a gamma 364 Asp→His (GAT-->CAT) substitution associated with defective fibrin polymerization. Thromb Haemost 1996; 75: 887-891.
• 12 Yoshida N. et al. Characterization of an abnormal fibrinogen Osaka V with the replacement of gamma-arginine 375 by glycine. The lack of high affinity calcium binding to D-domains and the lack of protective effect of calcium on fibrinolysis. J Biol Chem 1992; 267: 2753-2759.
• 13 Brennan SO. et al. Novel fibrinogen gamma375 Arg-->Trp mutation (fibrinogen aguadilla) causes hepatic endoplasmic reticulum storage and hypofibrinogenemia. Hepatology 2002; 36: 652-658.
• 14 Francalanci P. et al. Severe liver disease in early childhood due to fibrinogen storage and de novo gamma375Arg→Trp gene mutation. J Pediatr 2006; 148: 396-398.
• 15 Rubbia-Brandt L. et al. Fibrinogen gamma375 Arg→Trp mutation (fibrinogen Aguadilla) causes hereditary hypofibrinogenemia, hepatic endoplasmic reticulum storage disease and cirrhosis. Am J Surg Pathol 2006; 30: 906-911.
• 16 Bentolila S. et al. Association dysfibrinogénémie et thrombose. A propos d`un famille (Fibrinogène Melun) et revue de la littérature. Ann Med Interne 1995; 146: 575-580.
• 17 Lounes KC. et al. Fibrinogen Alès: a homozygous case of dysfibrinogenemia (γ-Asp330→Val) characterized by a defective fibrin polymerization site “a”. Blood 2000; 96: 3473-3479.
• 18 Lefebvre P. et al. Severe hypodysfibrinogenemia in compound heterozygotes of the fibrinogen AalphaIVS4 + 1G>T mutation and an AalphaGln328 truncation (fibrinogen Keokuk). Blood 2004; 103: 2571-2576.
• 19 Marchi RC. et al. A novel mutation (deletion of Aalpha-Asn 80) in an abnormal fibrinogen: fibrinogen Caracas VI. Consequences of disruption of the coiled coil for the polymerization of fibrin: peculiar clot structure and diminished stiffness of the clot. Blood Coagul Fibrinolysis 2004; 15: 559-567.
• 20 Brennan SO. et al. Aberrant hepatic processing causes removal of activation peptide and primary polymerization site from fibrinogen Canterbury (Aα Val→Asp). J Clin Invest 1995; 96: 2854-2858.
• 21 Kotlín R. et al. A novel fibrinogen variant--Liberec: dysfibrinogenaemia associated with gamma Tyr262Cys substitution. Eur J Haematol 2008; 81: 123-129.
• 22 Kotlín R. et al. Acquired dysfibrinogenemia secondary to multiple myeloma. Acta Haematol 2008; 120: 75-81.
• 23 Kotlín R. et al. A novel fibrinogen variant – Praha I: hypofibrinogenemia associated with γ351 Gly→Ser substitution. Eur J Haematol 2007; 78: 410-416.
• 24 Dyr JE. et al. Optical sensing of the initial stages in the growth and development of fibrin clot. Sens Actuators B Chem 2001; 74: 69-73.
• 25 Dyr JE. et al. Fibrinopeptide-releasing enzymes in the venom from the southern copperhead snake (agkistrodon-contortrix-contortrix). Toxicon 1989; 02: 359-373.
• 26 Dyr JE. et al. Molecular arrangement of adsorbed fibrinogen molecules characterized by specific monoclonal antibodies and a surface plasmon resonance sensor. Sens Actuators B Chem 1998; 51: 268-272.
• 27 Suttnar J. et al. Determination of fibrinopeptides by high performance liquid chromatography. Biochem Clin Bohemoslov 1989; 18: 17-25.
• 28 Miller SA. et al. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acid Res 1988; 16: 1215.
• 29 Vaníãková M. et al. The adhesion of blood platelets on fibrinogen surface: comparison of two biochemical microplate assays. Platelets 2006; 17: 470-476.
• 30 Kotlín R. et al. Fibrinogen Nový Jiãín and Praha II: Cases of hereditary Aalpha 16 Arg-->Cys and Aalpha 16 Arg-->His dysfibrinogenemia. Thromb Res 2007; 121: 75-84.
• 31 Kollman J. et al. Crystal structure of human fibrinogen. Biochemistry 2009; 48: 3877-3886.
• 32 Spraggon G. et al. Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin. Nature 1997; 389: 455-462.
• 33 Brown JH. et al. The crystal structure of modified bovine fibrinogen. Proc Natl Acad Sci USA 2000; 97: 85-90.
• 34 Doolittle RF. Fibrinogen and fibrin. Sci Am 1981; 245: 92-101.
• 35 Okumura N. et al. A novel variant fibrinogen, deletion of Bbeta111Ser in coiled-coil region, affecting fibrin lateral aggregation. Clin Chim Acta 2006; 365: 160-167.
• 36 Doolittle RF. et al. Designation of sequence involved in the coiled-coil interdomainal connections in fibrinogen: construction of an atomic scale model. J Mol Biol 1978; 120: 311-325.
• 37 Voskuilen M. et al. Fibrinogen lysine residue A alpha 157 plays a crucial role in the fibrin-induced acceleration of plasminogen activation, catalyzed by tissue-type plasminogen activator. J Biol Chem 1987; 262: 5944-5946.
• 38 Smith RA. et al. Evidence for new endothelial cell binding sites on fibrinogen. Thromb Haemost 2000; 84: 819-825.
• 39 Farrell DH. et al. Role of fibrinogen αand γ chain sites in platelet aggregation. Proc Natl Acad Sci USA 1992; 89: 10729-10732.
• 40 Medved L. et al. Conformational changes upon conversion of fibrinogen into fibrin: the mechanisms of exposure of some cryptic sites. Ann NY Acad Sci 2001; 936: 185-204.
• 41 Marder VJ, Francis CW. Plasmin degradation of cross-linked fibrin. Ann NY Acad Sci 1983; 408: 397-406.
• 42 Neerman-Arbez M. et al. Mutations in the fibrinogenAa gene account for the majority of cases of congenital afibrinogenemia. Blood 2000; 96: 149-152.
• 43 Neerman-Arbez M. et al. The 11 kb FGA deletion responsible for congenital afibrinogenaemia is mediated by a short direct repeat in the fibrinogen gene cluster. Eur J Hum Genet 1999; 07: 897-902.
• 44 Marchi RC. et al. A novel mutation (deletion of Aα−Asn80) in an abnormal fibrinogen: fibrinogen Caracas VI. Consequences of disruption of the coiled coil for the polymerization of fibrin: peculiar clot structure and diminished stiffness of the clot. Blood Coagul Fibrinol 2004; 15: 559-567.
• 45 Yamazumi K, Doolittle RF. Photoaffinity labeling of the primary fibrin polymerization site: Localization of the label to γ-chain Tyr-363. Proc Natl Acad Sci USA 1992; 89: 2893-2896.
• 46 Doolittle RF. et al. Difference in binding specificity for the homologous γ-and β-chain “holes” on fibrinogen: Exclusive binding of Ala-His-Pro-amide by the β-chain hole. Biochemistry 2006; 45: 13962-13969.